AIM2 Inhibits BRAF-Mutant Colorectal Cancer Growth in a Caspase-1-Dependent Manner

• Published in: Frontiers in cell and developmental biology Vol. 9; p. 588278
• Main Authors: Shah, Shailendra, Qin, Shaolan, Luo, Yang, Huang, Yizhou, Jing, Ran, Shah, Jay N, Chen, Jianjun, Chen, Huimin, Zhong, Ming
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 25.03.2021
• Subjects: absent in melanoma 2; BRAF-mutant; caspase-1; Cell and Developmental Biology; colorectal cancer; patient-derived organoids; patient-derived organoids; absent in melanoma 2; colorectal cancer; BRAF-mutant; caspase-1
• DOI: 10.3389/fcell.2021.588278
• ISSN: 2296-634X

Absent in melanoma 2 (AIM2), a DNA sensor that plays an important role in natural immunity system, has been reported to participate in colorectal cancer (CRC) development. However, the functional role of AIM2 in BRAF-mutant CRC remains unclear. In this study, we first investigated AIM2 expression level in BRAF-mutant CRC tumor tissues. Overexpression of AIM2 in CRC cells was performed to investigate the effect of AIM2 on CRC cell viability, and cell death detection and caspase activity assay were performed to explore the mechanism that AIM2 impacts the growth of BRAF-mutant CRC cells. Moreover, we confirmed the antitumor effect of AIM2 in BRAF-mutant CRC cell-derived tumor xenograft (CDX) models as well as patient-derived organoids (PDOs). Herein, we reported that AIM2 expression was lower in BRAF-mutant than that in BRAF wild-type CRC tumor tissues. Restoring the expression of AIM2 in BRAF-mutant CRC cells greatly inhibits the tumor cell growth by inducing necrotic cell death. Mechanism studies revealed that AIM2-induced cell death is in a caspase-1-dependent manner. Additionally, overexpression of AIM2 significantly inhibits tumor growth and metastasis in BRAF-mutant CRC , which was further confirmed in BRAF-mutant CRC PDOs. Taken together, our data suggested that AIM2 inhibits BRAF-mutant colon cancer growth in a caspase-1-dependent manner, which may provide evidence to understand the pathogenesis of CRC with BRAF-mutant, as well as new strategies for manipulation of CRC.